FDA will soon slash supplement filing requirements
This article was originally published in The Gold Sheet
Executive Summary
A sharp reduction in supplement filing requirements should result from a guidance FDA is preparing to issue in the next few months, Office of Pharmaceutical Science Director Helen Winkle told the PDA/FDA meeting in Washington on Sept. 24. The guidance "will make a big difference," Winkle said. "I couldn't believe how long the list was - about 50 different supplements that we will no longer be asking for." One caveat: There will be exceptions for "extra-complex" drug products
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.